Skip to content
March 29, 2024

Equity.Guru

Investment information for the new generation

Search

cybin

Cybin (CYBN.NEO), a Canadian-based biopharmaceutical company working to transform psychedelics into therapeutics, announced today that it had received approval from an independent ethics committee in the Netherlands to commence…
Filament Health (FH.NE) announced today that it has received approval from Health Canada for a Phase 2 clinical trial using PEX010, the Company’s botanical psilocybin drug candidate. Cybin Therapeutics…
We’re living in interesting times and I mean that in the Chinese curse kind of way. We can’t seem to stop to catch our breath when it comes to…
Revive Therapeutics (RVV.C) joined the AdvisorShares Psychedelics ETF (PSIL.NYSE) today, in time for its launch, according to a press release.   If you’re not entirely sure what an ETF…
“In business, cash is oxygen” – Gary Vaynerchuk   Psychedelics is a cash-intensive business. Earlier in the week, I wrote about how clinical trials alone cost companies tens, sometimes…
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news. Cybin (CYBN.NE) It’s been…
Cybin (CYBN.NE) announced they are filing a new non-provisional patent application, their 14th patent application. The decision comes after what they called “a favourable international search report” relating to…
Cybin (CYBN.NE) announced that they have received final approval from the New York Stock Exchange (NYSE) to list its shares on the NYSE American exchange. Beginning next Thursday, on…
Back in January of this year, we told you about a psychedelics company that was going to come at that sector like many had talked about, but few had…
Cybin (CYBN.NE) announced that they have received conditional approval to join the New York Stock Exchange (NYSE), specifically, the NYSE American LLC stock exchange. Cybin has reserved the ticker…